Boston Scientific intends to file an application with the FDA for approval of its Lotus valve system by year's end, one of two heart valves it hopes to get to the market in an effort to bring in over $1 billion in revenue. The company, which saw a 6% net sales increase driven by growth in its medical surgical supplies in the quarter ending June 30, also plans to launch a US trial of the ACURATE neo AS valve system.
Boston Scientific seeks growth in minimally invasive aortic valves
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.